Viromed Medical AG (Q11) — Cash Flow-to-Debt Ratio
Viromed Medical AG (Q11) has a Cash Flow-to-Debt Ratio of -0.14x as of September 2025, meaning its operating cash flow of €-10.12 Million could theoretically repay 0% of its total liabilities (€69.84 Million) in one year. See Q11 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Viromed Medical AG Cash Flow-to-Debt Ratio (2021–2024)
Historical debt coverage capacity for Viromed Medical AG across 4 annual periods. Also explore net asset momentum of Viromed Medical AG to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Viromed Medical AG (2021–2024)
Year-by-year debt coverage analysis for Viromed Medical AG. For market capitalisation and broader financial context, see Q11 market cap.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.11x | €-6.03 Million | €54.82 Million | ▲ +86.2% |
| 2023 | -0.80x | €-34.16 Million | €42.96 Million | ▲ +92.9% |
| 2022 | -11.17x | €-20.87 Million | €1.87 Million | ▼ -41.0% |
| 2021 | -7.92x | €-22.29 Million | €2.81 Million | — |